Showing 281-290 of 9351 results for "".
An Update on the Use of Minocycline for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/an-update-on-the-use-of-minocycline-for-the-treatment-of-acne/23201/Advances in formulation technology have led to the development of a stable topical minocycline that recently received FDA approval. Here’s what you should know.Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Scientifically Speaking: Can We Conquer Cellulite?
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-can-we-conquer-cellulite/19872/Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks with Nazanin Saedi, MD, Endo's Mike McLane, PhD, and Soliton's Wally Klemp.Update on Atopic Dermatitis 2018
https://practicaldermatology.com/topics/general-topics/update-on-atopic-dermatitis-2018/20354/A look at the pathophysiology of AD, including structural and immunologic contributors, as well as new therapeutic developments with an eye toward breakthroughs on the horizon.The Landscape for Vitiligo: An Interview with Larry Green, MD
https://practicaldermatology.com/topics/pigmentary-disorders/the-landscape-for-vitiligo-an-interview-with-larry-green-md/24209/Practical Dermatology® Chief Medical Editor Neal Bhatia, MD, FAAD, talked with Larry Green, MD, a board-certified dermatologist in private practice in Rockville, Maryland, about the latest in vitiligo treatment and what practitioners can tell their patients about recent advances in treatment for thiConversations in Acne, Part 2
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-2/19871/From isotretinoin to antibiotics—including next generation tetracyclines—the experts talk about key considerations for optimal outcomes, including the impact of diet. They also discuss management of trunk acne and strategies to reduce the risk for bacterial resistance. Host Neal Bhatia, MD leads theKnow Your Lesions: The Many Variations of Seborrheic Keratosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/know-your-lesions-the-many-variations-of-seborrheic-keratosis/20679/SKs are benign lesions that may be removed for medical or aesthetic reasons. It's essential to distinguish SKs from malignant lesions.Critical Factors to Advancing Melanoma Diagnosis and Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/critical-factors-to-advancing-melanoma-diagnosis-and-treatment/22970/Dermatologists need to stay abreast of technologies for evaluation of lesions and ensure that medical oncologists within their referral network recognize the importance of clinical trials.An Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. June